GSK Nov 2024 37.000 call
| Previous close | 9.30 |
| Open | 9.30 |
| Bid | 4.10 |
| Ask | 6.20 |
| Strike | 37.00 |
| Expiry date | 2024-11-15 |
| Day's range | 9.30 - 9.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 12 |
- Yahoo Finance Video
GSK stock sinks after court allows Zantac lawsuits to proceed
Shares of Britain-based pharmaceutical company GSK plc (GSK) — formerly known as GlaxoSmithKline — are sliding in pre-market trading and into Monday's session open following a court ruling that has approved more than 70,000 lawsuits to go forward over heartburn medication Zantac's alleged links to cancer. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
BloombergGSK Plunges as Drugmaker Must Face Zantac Cases in Delaware
(Bloomberg) -- GSK Plc shares plunged in the wake of a court ruling that the UK drugmaker, alongside others including Sanofi, must face trials over whether the former heartburn treatment Zantac causes cancer. Most Read from BloombergKey Engines of US Consumer Spending Are Losing Steam All at OnceGameStop Shares Surge as Gill’s Reddit Return Shows Huge BetMnuchin Chases Wall Street Glory With His War Chest of Foreign MoneyHomebuyers Are Starting to Revolt Over Steep Prices Across USAMLO Protege S
Business WireJemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer
